Dare Bioscience price target raised to $7 from $6 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Dare Bioscience to $7 from $6 and keeps a Buy rating on the shares. The announcement of the addition of DARE-PDM1, being developed for the treatment of primary dysmenorrhea, to the pipeline "signals to us that management intends to remain aggressive in its early pipeline work," Tsao tells investors in a research note.